Canaccord Genuity Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $143

Benzinga Newsdesk www.benzinga.com Positive 86.4%

Neg 0% Neu 0% Pos 86.4%

Canaccord Genuity analyst Whitney Ijem maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $140 to $143.